934660-67-0

Upstream product

• 833451-96-0 3,4-difluoro-2-[(2-fluoro-4-iodophenyl)amino]benzoyl chloride 
• 17557-84-5 3-oxoazetidine hydrochloride salt 
• 29632-74-4 2-fluro-4-iodoaniline 
• 391211-97-5 3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzoic acid 

Downstream Products

• 934660-93-2 [14C]-GDC-0973 
• 934660-94-3 cobimetinib 

Relevant academic research and scientific papers

Preparation method of cobimetinib

The invention discloses a preparation method of cobimetinib. The preparation method comprises the following steps of (1) performing oxidative coupling cyclization on acetone and ammonia water under the conditions of catalysis by iodized salt and protonic

A cappi for nepal chemical synthesis method

The invention belongs to the field of chemical synthesis and specifically relates to a preparation method for cobimetinib. The method comprises the following steps: by taking 2,3,4-benzyl trifluorobenzoate as an initial raw material, performing substitution reaction, deprotection reaction, amidation reaction and catalytic addition reaction, thereby obtaining the cobimetinib. The method provided by the invention has the advantages of easily-obtained and low-cost raw materials, short process flow, easiness in operation of industrial reaction, high yield, environmental protection and suitability for industrial batch production.

METHODS OF USING MEK INHIBITORS

The present invention provides methods of treating cancer by administering a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, in combination with other cancer treatments.

METHODS OF USING COMBINATIONS OF MEK AND JAK-2 INHIBITORS

A method of treating a disease in a mammal, comprising administering to the mammal a therapeutically effective amount of a MEK compound of Formula I(M), or a pharmaceutical composition comprising a therapeutically effective amount of a MEK compound of Formula I(M) and a pharmaceutically acceptable carrier, in combination with a therapeutically effective amount of a JAK-2 compound of Formula I(J), or a pharmaceutical composition comprising a therapeutically effective amount of a JAK-2 compound of Formula I(J) and a pharmaceutically acceptable carrier, wherein the MEK compound of Formula I(M) and JAK-2 compound of Formula I(J) are as defined in the specification.